Renal artery denervation, a new device-based therapeutic paradigm for managing treatment resistant hypertension, has come of age and is attracting an unprecedented gold rush from serial medical device entrepreneurs.
Medtronic's acquisition of Ardian for $800 million plus $500 million more in milestone payments in January 2011 signaled the dawning of a new era of catheter-based renal denervation systems.
Results of the Symplicity HTN-1 and Symplicity HTN-2 trials have generated considerable interest among physicians, patients, medical device entrepreneurs, and the investment community.
The market, although still in the inception phase, has already attracted heavy hitters with Covidien paying $230 Million for Maya Medical' OneShot renal denervation system, St. Jude launching its EnligHTN renal denervation system in Europe in May 2012 and Boston Scientific diverting its R&D resources for a first-in-man with a new device before the end of 2012.
Renal denervation is a catheter-based therapy that uses either radiofrequency or ultrasound energy to disrupt the renal arteries sympathetic nerves whose hyperactivity may lead to treatment-resistant hypertension.
Renal denervation systems are perhaps the hottest medical device innovation space this year as they offer a complementary approach to the management of resistant hypertension that was not available before.
Renal Denervation Market - Current Situation & Future Outlook attempts to answer some important questions regarding the fast evolving market by examining Leading companies technologies, product offerings, market shares. The report offers a credible forecast to 2016.
With Renal Denervation Market report you’ll be better able to:
Examine this new strategic landscape and understand its market dynamics.
Assess market size, growth rates and market potential.
Get your hand on the first credible forecast for this fast evolving segment.
Identify emerging technologies and the companies behind them.
Leverage your own technology and brainstorm new business opportunities.
Monitor the competition’s marketed and in-development products.
Investigate mergers, acquisitions and licensing possibilities.
Renal Denervation Market report is targeted at senior executives in the medical device space, innovators, serial medtech entrepreneurs and ventures capitalists who wish to get a handle on this potentially $3 billion fast growing opportunity.